Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise

Immune checkpoint inhibitors are monoclonal antibodies that are used to treat over one in three cancer patients. While they have changed the natural history of disease, prolonging life and preserving quality of life, they are highly active in less than 40% of patients, even in the most responsive ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Healey Bird, Brian, Nally, Ken, Ronan, Karine, Clarke, Gerard, Amu, Sylvie, Almeida, Ana S., Flavin, Richard, Finn, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775044/
https://www.ncbi.nlm.nih.gov/pubmed/35054292
http://dx.doi.org/10.3390/diagnostics12010124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775044/
https://www.ncbi.nlm.nih.gov/pubmed/35054292
http://dx.doi.org/10.3390/diagnostics12010124

Ejemplares similares